Line
Why Industry Clinical Trials Are Stopped
Share of company-led trials terminated over the past 12 months whose stated reason cites each cause, %
Plays the chart through its history. Pauses are where the data set a record or moved most.
ClinicalTrials.gov. Company-led interventional trials that ended, over the 12 months to each month; the newest three months are held back while late reports arrive. Reasons are the sponsor's own words, labelled by fixed word rules; a stop can cite more than one.
Money, patients or the drug itself. When biotech funding tightens or big pharma reshuffles its pipeline, the business line rises; scientific failures show up in the safety-or-efficacy line.
What this chart reads
- Industry Trials Stopped for Business or Funding Reasons (% of Stops)as “Business or funding”latest 2026-06-01
- Industry Trials Stopped for Enrollment Problems (% of Stops)as “Enrollment”latest 2026-06-01
- Industry Trials Stopped for Safety or Efficacy (% of Stops)as “Safety or efficacy”latest 2026-06-01
Sources
Industry Trials Stopped for Business or Funding Reasons (% of Stops). Source: ClinicalTrials.gov (U.S. National Library of Medicine), API v2, refreshed weekly. Palanor counts and classifies the records as described above; it does not change them. ClinicalTrials.gov disclaimer: the U.S. government does not review or approve the safety and science of all studies listed; sponsors and investigators are responsible for their listings.
Industry Trials Stopped for Enrollment Problems (% of Stops). Source: ClinicalTrials.gov (U.S. National Library of Medicine), API v2, refreshed weekly. Palanor counts and classifies the records as described above; it does not change them. ClinicalTrials.gov disclaimer: the U.S. government does not review or approve the safety and science of all studies listed; sponsors and investigators are responsible for their listings.
Industry Trials Stopped for Safety or Efficacy (% of Stops). Source: ClinicalTrials.gov (U.S. National Library of Medicine), API v2, refreshed weekly. Palanor counts and classifies the records as described above; it does not change them. ClinicalTrials.gov disclaimer: the U.S. government does not review or approve the safety and science of all studies listed; sponsors and investigators are responsible for their listings.
Charts are drawn from Palanor's signal library and recomputed from source data on every view. Transformations (changes, indexing, year-on-year rates) are Palanor's.